| Cash Flow | 2025-06-30 |
|---|---|
| Stock- based compensation | 131,490 |
| Non-cash rent expense | 0 |
| Net loss | -4,468,247 |
| Issuance of common stock pursuant to vendor agreements | 210,400 |
| Vendor deposits | 8,700 |
| Prepaid expenses and other current assets | 193,876 |
| Operating lease liability | 0 |
| Accrued expenses and other current liabilities | 961,545 |
| Accounts payable | 56,208 |
| Depreciation of fixed assets | 0 |
| Deferred tax provision | 0 |
| Net cash used in operating activities | -3,293,780 |
| Exercise of warrants | 0 |
| Private placement of warrants | 1,999,791 |
| Deferred offering costs | 17,928 |
| Registration and issuance costs associated with warrant issuance | 147,131 |
| Exercise of pre-funded warrants | 210 |
| Net cash provided by financing activities | 1,834,942 |
| Net decrease in cash | -1,458,838 |
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)